Charter Rights, Medical Necessity, and Section 56: A Legal and Constitutional Analysis of Canadian Psychedelic Policy (2020–2026)
Executive Summary
Under the Controlled Drugs and Substances Act (CDSA), the Federal Minister of Health possesses the discretionary power under Section 56(1) to grant exemptions for medical or scientific purposes. Beginning in August 2020 with exemptions for four terminally ill Canadians, constitutional challenges under Section 7 of the Canadian Charter of Rights and Freedoms ('Life, Liberty, and Security of the Person') have steadily expanded patient rights and established a blueprint for federal decriminalization.
1. Historical Milestones in Canadian Psychedelic Jurisprudence
Canada has historically pioneered evidence-based progressive drug policy, from the legalization of medical cannabis in 2001 to the opening of North America's first supervised consumption site (InSite in Vancouver, 2003).
The legal journey of psilocybin mirrors this progression, transitioning from absolute prohibition to therapeutic necessity and municipal non-enforcement priorities.
Primary Scientific Citations
- Tousignant, C., & Walsh, Z. (2022). Medicalization and Policy Reform of Psychedelics in Canada: A Public Health and Human Rights Perspective. Canadian Journal of Public Health • DOI: 10.17269/s41997-022-00624-9